奥替溴铵联合氟哌噻吨美利曲辛治疗腹泻型肠易激综合征的临床效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Otilonium Bromide combined with Flupenthixol Melitracen in treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).Methods A total of 96 patients diagnosed with IBS-D in our hospital from January 2014 to December 2016 were randomly divided into the observation group(52 cases)and the control group (44 cases).The control group was treated with Otilonium Bromide,while the observation group was treated with Otilonium Bromide combined with Flupenthixol Melitracen.The course of each group was 4 weeks.After treatment,the efficacy of the two groups of patients was compared,and the mental and psychological states of the two groups of patients were analyzed and evaluated by the hospital anxiety-depression scale (HADS).ResultsThe overall curative effect of the observation group was better than that of the control group,and the difference was statistically significant(P＜0.05).The total effective rate of the control group was 75.0%(33/44),and the total effective rate of the treatment group was 88.5%(47/52),comparison of total therapeutic efficiency between the two groups showed no statistically significant difference(P＞0.05).The anxiety score of the control group was(8.14±1.36)points before treatment and(6.42±1.67)points after treatment,the anxiety score of the observation group was(8.35±1.44)points before treatment and(5.38±1.28)points after treatment.The depression score of the control group was(9.56±1.93)points before treatment and(6.89±2.02)points after treatment.The depression score of the observation group was(9.68±1.81)points before treatment and(5.56±1.73)points after treatment.After treatment,the anxiety and depression scores of both groups were lower than those before treatment and those of the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions was 4.5%in the control group and 5.8%in the treatment group,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment of Otilonium Bromide combined with Flupenthixol Melitracen has a more pronounced effect on IBS-D patients and the symptoms of anxiety and depression can be improved significantly.

Key words： Otilonium Bromide Flupenthixol Melitracen Diarrhea-predominant irritable bowel syndrome Anxiety and depression

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YIN Chun-li

Cite this article:

YIN Chun-li. Clinical effect of Otilonium Bromide combined with Flupenthixol Melitracen in treatment of diarrhea-predominant irritable bowel syndrome[J]. 中国当代医药, 2018, 25(19): 154-157.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I19/154

[1]	李莉，熊理守.肠易激综合征的流行病学调查[J].中华消化杂志，2015，35（7）：446-450.
[2]	Sarah B，Alyse B，Laurie K.Psychosocial impact of irritable bowel syndrome：A brief review[J].World J Gastrointest Pathophysiol，2015，6（4）：120-123.
[3]	赵向阳.美沙拉嗪治疗难治性腹泻型肠易激综合征28例临床观察[J].中外医学研究，2012，10（33）：126-127.
[4]	魏双琴，施建平，金怒云，等.医院焦虑抑郁量表应用于治疗肠易激综合征的意义[J].中国医药导报，2013，10（34）：154-156.
[5]	何宛蓉，张法灿，梁列新.肠易激综合征流行病学研究现状与进展[J].胃肠病学和肝病学杂志，2012，21（1）：83-88.
[6]	Soares R L.Irritable bowel syndrome：A clinical review[J].World J Gastroenterol，2014，20（34）：12144-12160.
[7]	Elsalhy M.Recent developments in the pathophysiology of irritable bowel syndrome[J].World J Gastroenterol，2015，21（25）：7621-7636.
[8]	刘建庄.肠易激综合征患者个性和心理因素研究[J].中国实用医药，2015，10（11）：269-270.
[9]	王超，王巧民，宋继中，等.肠易激综合征患者精神心理因素对生活质量、睡眠质量以及症状严重程度的影响[J].胃肠病学，2016，21（1）：34-38.
[10]	Roohafza H，Bidaki EZ，Hasanzadeh-Keshteli A，et al.Anxiety，depression and distress among irritable bowel syndrome and their subtypes：an epidemiological population based study[J].Adv Biomed Res，2016，5（1）：183.
[11]	Gao J.Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome[J].Exp Ther Med，2013，6（1）：93-96.
[12]	SpenceMeaganJ，Moss-MorrisRona.Thecognitivebehavioural model of irritable bowel syndrome：a prospective investigation of patients with gastroenteritis[J].Gut，2007，56（8）：1066-1071.
[13]	黄宣，吕宾.肠易激综合征诊治进展和面临的挑战[J].世界华人消化杂志，2010，18（21）：2234-2239.
[14]	Khazeni N，Perlroth D.Rifaximin for irritable bowel syndrome without constipation[J].N Engl J Med，2011，364（15）：1467-1468.
[15]	陈雪娥，王承党.选择性钙通道拮抗剂治疗肠易激综合征疗效和安全性的Meta分析[J].中国循证医学杂志，2015，15（7）：840-846.
[16]	Boeckxstaens G，Clavé P，Corazziari ES，et al.Irritable bowel syndrome：focus on otilonium bromide[J].Expert Rev Gastroenterol Hepatol，2014，8（2）：131-137.
[17]	吉训恋.氟哌噻吨美利曲辛用于腹泻型肠易激综合征患者效果观察[J].山东医药，2015，55（10）：66-67.
[18]	孙兆双，孙丹丹.中西医结合治疗腹泻型肠易激综合征的临床研究[J].中国当代医药，2016，23（34）：136-138.
[19]	谢俊峰，胡云淑.硫糖铝片联合双歧杆菌三联活菌胶囊治疗腹泻型肠易激综合征的临床效果[J].中国当代医药，2017，24（14）：109-111.
[20]	余水平.小剂量米氮平与奥替溴铵联合用药治疗腹泻型肠易激综合征的临床效果[J].中外医学研究，2017，15（4）：111-112.
[21]	陆桢.马来酸曲美布汀治疗肠易激综合征随机对照试验的 Meta 分析[J].中外医学研究，2017，15（10）：11-15.
[22]	肖修玲.黛力新对肠易激综合征焦虑抑郁状态的疗效及对血管活性肠肽表达水平的影响究，2017，15（18）：33-34.